Zhang Lixia, Liu Weiwei, Wang Xinbo, Wang Xiaoli, Sun Hong
Department of Gynaecology, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China.
Department of Gynaecology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China.
Oncol Lett. 2019 Feb;17(2):2365-2369. doi: 10.3892/ol.2018.9842. Epub 2018 Dec 18.
Prognostic value of serum interleukin-8 (IL-8) and interleukin-10 (IL-10) in patients with ovarian cancer undergoing chemotherapy was evaluated. The clinical data of ovarian tumor patients in Yidu Central Hospital of Weifang treated from January 2012 to December 2014 was retrospectively analyzed, 92 cases of which were malignant group, 64 cases were benign group, and 58 healthy subjects were selected as control group. Serum expression levels of IL-8 and IL-10 of the three groups were detected by enzyme-linked immunosorbent assay. Serum expression levels of IL-8 and IL-10 in benign and malignant groups both were higher than those in healthy control group (P<0.001). Serum expression levels of IL-8 and IL-10 of patients with ovarian cancer at III+IV stage were higher than that at I+II stage (P<0.001). Serum expression levels of IL-8 and IL-10 of patients with malignant ovarian tumors before chemotherapy were higher than those after chemotherapy (P<0.001). Serum levels of IL-8 and IL-10 of patients with malignant ovarian tumors in stable condition after chemotherapy were lower than those with recurrence and metastasis after chemotherapy (P<0.001). The median of serum expression levels of IL-8 and IL-10 was divided into low expression group and high expression group. The survival time of patients in high serum IL-8 and IL-10 expression group was significantly shorter than that in serum IL-8 and IL-10 low expression group (P<0.05). The survival time was negatively correlated with the expression levels of IL-8 and IL-10. Serum expression levels of IL-8 and IL-10 are closely related to the stages and prognosis of ovarian cancer. IL-8 and IL-10 may be involved in the occurrence and development of ovarian cancer. There are certain reference values on the changes of IL-8 and IL-10 levels, which may reflect the biological behavior and prognosis of ovarian cancer.
评估血清白细胞介素-8（IL-8）和白细胞介素-10（IL-10）在接受化疗的卵巢癌患者中的预后价值。回顾性分析2012年1月至2014年12月在潍坊市益都中心医院治疗的卵巢肿瘤患者的临床资料，其中恶性组92例，良性组64例，选取58例健康受试者作为对照组。采用酶联免疫吸附测定法检测三组血清中IL-8和IL-10的表达水平。良性组和恶性组血清IL-8和IL-10表达水平均高于健康对照组（P<0.001）。Ⅲ+Ⅳ期卵巢癌患者血清IL-8和IL-10表达水平高于Ⅰ+Ⅱ期患者（P<0.001）。恶性卵巢肿瘤患者化疗前血清IL-8和IL-10表达水平高于化疗后（P<0.001）。化疗后病情稳定的恶性卵巢肿瘤患者血清IL-8和IL-10水平低于化疗后复发转移患者（P<0.001）。将血清IL-8和IL-10表达水平的中位数分为低表达组和高表达组。血清IL-8和IL-10高表达组患者的生存时间明显短于血清IL-8和IL-10低表达组患者（P<0.05）。生存时间与IL-8和IL-10表达水平呈负相关。血清IL-8和IL-10表达水平与卵巢癌的分期及预后密切相关。IL-8和IL-10可能参与卵巢癌的发生发展。IL-8和IL-10水平的变化有一定参考价值，可能反映卵巢癌的生物学行为及预后。
